Southpoint Capital Advisors’s 10x Genomics TXG Stock Holding History

Southpoint Capital Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-400,000	Closed	-$7.78M	–	53
2024 Q2	$7.78M	Sell	400,000 -300,000	-43%	-$7.86M	0.19%	44
2024 Q1	$26.3M	Buy	+700,000	New	+$30.8M	0.52%	47
2023 Q1	–	Sell	-300,000	Closed	-$10.9M	–	66
2022 Q4	$10.9M	Buy	+300,000	New	+$9.81M	0.28%	49

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Southpoint Capital Advisors's TXG Position: Q3 2024 in Review

Southpoint Capital Advisors sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 400,000 shares — an estimated $7.78M sold.

Southpoint Capital Advisors first reported a position in TXG in Q4 2022 and held it in 3 quarters. The position peaked at $26.3M in Q1 2024. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

Southpoint Capital Advisors reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
Southpoint Capital Advisors sold 400,000 10x Genomics shares in Q3 2024, an estimated $7.78M.
Southpoint Capital Advisors first reported a position in 10x Genomics in Q4 2022 and held it in 3 quarters.
Southpoint Capital Advisors's 10x Genomics position peaked at $26.3M in Q1 2024.
266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on Southpoint Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.